Video

Challenges of Implementing PSMA-Targeted PET Imaging in Prostate Cancer

Author(s):

Phillip Koo, MD,Michael S. Cookson, MD, MMHC, FACS

Dr Cookson discusses the challenges of using PSMA-PET imaging in prostate cancer, including reimbursement and patient access.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Laura Davis, MD, on persistent poverty and early onset prostate cancer
Laura Davis, MD, on persistent poverty and early onset prostate cancer
Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
Ruben Olivares, MD, answers a question during a Zoom video interview
Ruben Olivares, MD, discusses HIFU and remote prostate cancer care
Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Post-RP incontinence: Low procedure rates examined
Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
Data link incontinence severity to post-radical prostatectomy care
Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Expert discusses differentiating prostate cancer from age-related issues
Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
Related Content
FDA logo
July 3rd 2025

FDA news recap in urology for Q2 2025

Hannah Clarke Benjamin P. Saylor Jason M. Broderick
Here’s a look back at notable news between April and June 2025.
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
Gedatolisib plus darolutamide shows encouraging activity in mCRPC
July 1st 2025

Gedatolisib plus darolutamide shows encouraging activity in mCRPC

Hannah Clarke
The combination demonstrated a 6-month radiographic progression-free survival of 66%.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
What urologists can expect in Q3 of 2025
June 30th 2025

What urologists can expect in Q3 of 2025

Benjamin P. Saylor Hannah Clarke
A comprehensive guide to the key regulatory decisions and conferences slated for Q3 of 2025.
Conceptual image for viral ethiology of prostate cancer. 3D illustration showing Human Papilloma Viruses HPV infecting prostate gland which develops cancerous tumor | Image Credit: © Dr_Microbe - stock.adobe.com
June 27th 2025

Biden’s prostate cancer diagnosis underscores importance of screening, awareness

Hannah Clarke
The unfortunate news of President Biden’s diagnosis has put a spotlight on prostate cancer, offering an opportunity to educate on the risks of the disease and the benefits of screening.
© 2025 MJH Life Sciences

All rights reserved.